Pulse Biosciences (NASDAQ:PLSE) Raised to “Hold” at Wall Street Zen

Pulse Biosciences (NASDAQ:PLSE) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday, Wall Street Zen reports.

PLSE has been the subject of several other research reports. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research report on Monday, August 10th. Canaccord Genuity Group upped their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Finally, Needham & Company LLC began coverage on Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Stock Performance

Shares of PLSE stock opened at $53.24 on Friday. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $55.37. The company’s 50-day moving average price is $38.45 and its 200-day moving average price is $28.25. The stock has a market cap of $3.68 billion, a price-to-earnings ratio of -45.12 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. As a group, equities research analysts predict that Pulse Biosciences will post -1.29 EPS for the current year.

Insider Buying and Selling at Pulse Biosciences

In related news, COO Liane Teplitsky purchased 1,001 shares of Pulse Biosciences stock in a transaction dated Tuesday, September 1st. The shares were acquired at an average cost of $49.95 per share, with a total value of $49,999.95. Following the purchase, the chief operating officer owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have bought 4,095 shares of company stock worth $199,931 in the last ninety days. 74.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Pulse Biosciences in the second quarter valued at approximately $40,672,000. Bank of America Corp DE purchased a new position in shares of Pulse Biosciences during the second quarter worth $40,115,000. California State Teachers Retirement System grew its stake in shares of Pulse Biosciences by 2,600.0% in the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock valued at $15,747,000 after buying an additional 546,850 shares in the last quarter. State Street Corp grew its stake in shares of Pulse Biosciences by 6.0% in the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after buying an additional 25,187 shares in the last quarter. Finally, Brooklyn Investment Group raised its holdings in shares of Pulse Biosciences by 330.7% in the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after buying an additional 100,081 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.